ASX:BOT

Botanix Pharmaceuticals Competitors

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume1.63 million shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Botanix Pharmaceuticals (ASX:BOT) Vs. CHV, DDXS, PREV, TNGN, COM, and MYM

Should you be buying BOT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Botanix Pharmaceuticals, including (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), and 17031 (MYM).

Botanix Pharmaceuticals vs. (CHV) Stock

Botanix Pharmaceuticals (ASX:BOT) and (CHV) (CNSX:CHV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.

Valuation and Earnings

This table compares Botanix Pharmaceuticals and (CHV)'s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Botanix Pharmaceuticals	$6.89 million	0.00	$-9,731,420.16	A($0.01)	N/A
(CHV)	N/A	N/A	N/A	N/A	N/A

(CHV) has lower revenue, but higher earnings than Botanix Pharmaceuticals.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Botanix Pharmaceuticals and (CHV), as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Botanix Pharmaceuticals	0	0	0	0	N/A
(CHV)	0	0	0	0	N/A

Profitability

This table compares Botanix Pharmaceuticals and (CHV)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Botanix Pharmaceuticals	N/A	N/A	N/A
(CHV)	N/A	N/A	N/A

Summary

Botanix Pharmaceuticals beats (CHV) on 1 of the 1 factors compared between the two stocks.

Botanix Pharmaceuticals vs. (DDXS) Stock

Botanix Pharmaceuticals (ASX:BOT) and (DDXS) (OTCMKTS:DDXS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.

Profitability

This table compares Botanix Pharmaceuticals and (DDXS)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Botanix Pharmaceuticals	N/A	N/A	N/A
(DDXS)	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Botanix Pharmaceuticals and (DDXS), as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Botanix Pharmaceuticals	0	0	0	0	N/A
(DDXS)	0	0	0	0	N/A

Valuation and Earnings

This table compares Botanix Pharmaceuticals and (DDXS)'s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Botanix Pharmaceuticals	$6.89 million	0.00	$-9,731,420.16	A($0.01)	N/A
(DDXS)	N/A	N/A	N/A	N/A	N/A

(DDXS) has lower revenue, but higher earnings than Botanix Pharmaceuticals.

Summary

Botanix Pharmaceuticals beats (DDXS) on 1 of the 1 factors compared between the two stocks.

Botanix Pharmaceuticals vs. (PREV) Stock

(PREV) (CNSX:PREV) and Botanix Pharmaceuticals (ASX:BOT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.

Profitability

This table compares (PREV) and Botanix Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(PREV)	N/A	N/A	N/A
Botanix Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for (PREV) and Botanix Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(PREV)	0	0	0	0	N/A
Botanix Pharmaceuticals	0	0	0	0	N/A

Valuation & Earnings

This table compares (PREV) and Botanix Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(PREV)	N/A	N/A	N/A	N/A	N/A
Botanix Pharmaceuticals	$6.89 million	0.00	$-9,731,420.16	A($0.01)	N/A

(PREV) has higher earnings, but lower revenue than Botanix Pharmaceuticals.

Summary

Botanix Pharmaceuticals beats (PREV) on 1 of the 1 factors compared between the two stocks.

Botanix Pharmaceuticals vs. (TNGN) Stock

(TNGN) (OTCMKTS:TNGN) and Botanix Pharmaceuticals (ASX:BOT) are both health technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.

Profitability

This table compares (TNGN) and Botanix Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
(TNGN)	N/A	N/A	N/A
Botanix Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for (TNGN) and Botanix Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
(TNGN)	0	0	0	0	N/A
Botanix Pharmaceuticals	0	0	0	0	N/A

Valuation & Earnings

This table compares (TNGN) and Botanix Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
(TNGN)	N/A	N/A	N/A	N/A	N/A
Botanix Pharmaceuticals	$6.89 million	0.00	$-9,731,420.16	A($0.01)	N/A

(TNGN) has higher earnings, but lower revenue than Botanix Pharmaceuticals.

Summary

Botanix Pharmaceuticals beats (TNGN) on 1 of the 1 factors compared between the two stocks.

Botanix Pharmaceuticals vs. 138267 (COM.TO) Stock

138267 (COM.TO) (TSE:COM) and Botanix Pharmaceuticals (ASX:BOT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.

Profitability

This table compares 138267 (COM.TO) and Botanix Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
138267 (COM.TO)	N/A	N/A	N/A
Botanix Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for 138267 (COM.TO) and Botanix Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
138267 (COM.TO)	0	0	0	0	N/A
Botanix Pharmaceuticals	0	0	0	0	N/A

Valuation & Earnings

This table compares 138267 (COM.TO) and Botanix Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
138267 (COM.TO)	N/A	N/A	N/A	N/A	N/A
Botanix Pharmaceuticals	$6.89 million	0.00	$-9,731,420.16	A($0.01)	N/A

138267 (COM.TO) has higher earnings, but lower revenue than Botanix Pharmaceuticals.

Summary

Botanix Pharmaceuticals beats 138267 (COM.TO) on 1 of the 1 factors compared between the two stocks.

Botanix Pharmaceuticals vs. 17031 Stock

17031 (CNSX:MYM) and Botanix Pharmaceuticals (ASX:BOT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for 17031 and Botanix Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
17031	0	0	0	0	N/A
Botanix Pharmaceuticals	0	0	0	0	N/A

Profitability

This table compares 17031 and Botanix Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
17031	N/A	N/A	N/A
Botanix Pharmaceuticals	N/A	N/A	N/A

Valuation & Earnings

This table compares 17031 and Botanix Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
17031	N/A	N/A	N/A	N/A	N/A
Botanix Pharmaceuticals	$6.89 million	0.00	$-9,731,420.16	A($0.01)	N/A

17031 has higher earnings, but lower revenue than Botanix Pharmaceuticals.

Summary

Botanix Pharmaceuticals beats 17031 on 1 of the 1 factors compared between the two stocks.